The Pharma Data

OCTOBER 28, 2020

log10 copies/mL greater reduction with REGN-COV2 compared to placebo (combined dose groups; p<0.0001). log10 copies/mL greater reduction with REGN-COV2 compared to placebo (combined dose groups; p=0.0003). placebo; p=0.024). There was a 1.08 combined dose groups; 6.5%

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

DECEMBER 29, 2020

The results passed the futility analysis (p<0.3 log 10 copies/mL (nominal p=0.002 for combined doses). log 10 copies/mL (nominal p=0.002 for combined doses). The criteria for ‘high-risk’ patients are described in the Fact Sheet for Healthcare Providers. futility analysis).

Antibody 52

Antibody Trials Production Clinical Trials 52

The Pharma Data

NOVEMBER 20, 2020

and plan to submit applications immediately to other regulatory agencies around the world. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 1, 2020

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. 2, 2020 07:05 UTC. NEW YORK & MAINZ, Germany–( BUSINESS WIRE )– Pfizer Inc. The companies have filed a request for Emergency Use Authorization with the U.S.

Vaccination 40

Vaccination Vaccine Manufacturing Clinical Trials 40

Drug Discovery World

NOVEMBER 9, 2023

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen. Filip Borgions, Ph.D,

Engineer 52

Engineer Antibody Protein In-Vivo 52